Chen C - Search Results

1

A quantitative systems pharmacology model of colonic motility with applications in drug development.

Das R, Wille L, Zhang L, Chen C, Winchester W, Selimkhanov J, Wykosky J, Apgar JF, Burke JM, Rogge M, Hua F, Vakilynejad M. Das R, et al. Among authors: chen c. J Pharmacokinet Pharmacodyn. 2019 Oct;46(5):485-498. doi: 10.1007/s10928-019-09651-6. Epub 2019 Aug 20. J Pharmacokinet Pharmacodyn. 2019. PMID: 31432345

2

Evaluation of the Pharmacokinetics of Felcisetrag (TAK-954), a 5-HT₄ Receptor Agonist, in the Presence and Absence of Itraconazole, a Potent CYP3A4 Inhibitor.

Chen C, Zhang L, Almansa C, Rosario M, Cwik M, Balani SK, Lock R. Chen C, et al. Clin Pharmacol Drug Dev. 2022 Feb;11(2):142-149. doi: 10.1002/cpdd.1046. Epub 2022 Jan 6. Clin Pharmacol Drug Dev. 2022. PMID: 34989180 Clinical Trial.

3

Randomised study: effects of the 5-HT₄ receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis.

Chedid V, Brandler J, Arndt K, Vijayvargiya P, Wang XJ, Burton D, Harmsen WS, Siegelman J, Chen C, Chen Y, Almansa C, Dukes G, Camilleri M. Chedid V, et al. Among authors: chen c, chen y. Aliment Pharmacol Ther. 2021 May;53(9):1010-1020. doi: 10.1111/apt.16304. Epub 2021 Mar 12. Aliment Pharmacol Ther. 2021. PMID: 33711180 Free PMC article. Clinical Trial.

4

Evaluation of the pharmacokinetics of trazpiroben (TAK-906) in the presence and absence of the proton pump inhibitor esomeprazole.

Kaur Mukker J, Dukes G, Wang L, Huh S, Khudyakov P, Nishihara M, Chen C. Kaur Mukker J, et al. Among authors: chen c. Clin Transl Sci. 2022 May;15(5):1281-1290. doi: 10.1111/cts.13248. Epub 2022 Feb 26. Clin Transl Sci. 2022. PMID: 35218604 Free PMC article.

5

CSTI-300 (SMP-100); a Novel 5-HT₃ Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid Syndrome.

Roberts A, Grafton G, Powell AD, Brock K, Chen C, Xie D, Huang J, Liu S, Cooper AJ, Brady CA, Qureshi O, Stamataki Z, Manning DD, Moore NA, Sargent BJ, Guzzo PR, Barnes NM. Roberts A, et al. Among authors: chen c. J Pharmacol Exp Ther. 2020 Apr;373(1):122-134. doi: 10.1124/jpet.119.261008. Epub 2020 Feb 26. J Pharmacol Exp Ther. 2020. PMID: 32102919

6

Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D₂ /D₃ receptor antagonist, in patients with gastroparesis.

Kuo B, Scimia C, Dukes G, Zhang W, Gupta S, Chen C, Chuang E, Camilleri M. Kuo B, et al. Among authors: chen c. Aliment Pharmacol Ther. 2021 Aug;54(3):267-280. doi: 10.1111/apt.16451. Epub 2021 Jun 20. Aliment Pharmacol Ther. 2021. PMID: 34148244 Clinical Trial.

7

Evaluation of the Pharmacokinetics of Trazpiroben (TAK-906), a Peripherally Selective D₂/D₃ Dopamine Receptor Antagonist, in the Presence and Absence of Itraconazole, a Potent CYP 3A4 Inhibitor.

Chen C, Zhang W, Bari M, Almansa C, Baratta M, Rosario M. Chen C, et al. Clin Pharmacol. 2021 Jul 12;13:145-155. doi: 10.2147/CPAA.S310609. eCollection 2021. Clin Pharmacol. 2021. PMID: 34285598 Free PMC article. Clinical Trial.

8

Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study.

Hyams JS, Turner D, Cohen SA, Szakos E, Kowalska-Duplaga K, Ruemmele F, Croft NM, Korczowski B, Lawrence P, Bhatia S, Kadali H, Chen C, Sun W, Rosario M, Kabilan S, Treem W, Rossiter G, Lirio RA. Hyams JS, et al. Among authors: chen c. J Crohns Colitis. 2022 Aug 30;16(8):1243-1254. doi: 10.1093/ecco-jcc/jjac036. J Crohns Colitis. 2022. PMID: 35301512 Free PMC article. Clinical Trial.

9

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.

Chen YB, Shah NN, Renteria AS, Cutler C, Jansson J, Akbari M, Chen C, Quadri S, Parfionovas A, Devine SM. Chen YB, et al. Among authors: chen c. Blood Adv. 2019 Dec 10;3(23):4136-4146. doi: 10.1182/bloodadvances.2019000893. Blood Adv. 2019. PMID: 31821456 Free PMC article. Clinical Trial.

10

The pharmacokinetics of oral trazpiroben (TAK-906) after organic anion transporting polypeptide 1B1/1B3 inhibition: A phase I, randomized study.

Mukker JK, Dukes G, Tolkoff M, Wang L, Almansa C, Huh SY, Nishihara M, Ramsden D, Chen C. Mukker JK, et al. Among authors: chen c. Clin Transl Sci. 2022 Jun;15(6):1532-1543. doi: 10.1111/cts.13274. Epub 2022 May 5. Clin Transl Sci. 2022. PMID: 35460165 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

85,724 results

Search Page